BACKGROUND: Hypoxia-inducible factor-1 (HIF-1) is a master regulator of the transcriptional response to oxygen deprivation and controls genes involved in glycolysis, angiogenesis, migration and invasion. Overexpression of HIF-1a has been demonstrated in many common human cancers.
Introduction
Hypoxia is a common feature of almost all types of solid tumors including prostate, brain, breast, colon and pancreas.
1,2 Overexpression of hypoxia-inducible factor-1 (HIF-1) is a common feature of solid malignancies related to oxygen deficiencies occurring through multiple mechanisms, including increasing proliferation of tumor cells, lack of oxygen diffusion, decreased blood flow and abnormal tumor vasculature. 3, 4 HIF-1 is a heterodimer of a hypoxia-stabilized and activated asubunit and an oxygen-insensitive b-subunit. Therefore, the biological activity of HIF-1 is determined by HIF-1a expression. 5 In normoxia, HIF-1a is rapidly ubiquitinated by the von Hippel-Lindau E3 ligase complex and subjected to proteasomal degradation. However, under hypoxic conditions, HIF-1a is not degraded and accumulates to form transcriptionally active complexes with HIF-1b.
Hypoxia-inducible factor-1 is the most important regulator of vascular endothelial growth factor (VEGF) expression by binding to the hypoxia response element (HRE) in the VEGF promoter. 6 VEGF has been recognized as the most important inducer of angiogenesis, and has an important role in tumor progression. In addition to serving as a response to hypoxic stress, increased expression of HIF target genes by tumor cells may provide an advantage to them such as undergoing proliferation, differentiation or development. 7 Zhong et al. 8 have already demonstrated that activation of the phosphoinositide kinase 3 (PI3K)/phosphatase and tensin homolog (PTEN)/Akt pathway by serum or autocrine stimulation results in increased expression of HIF-1a protein, HIF-1 transcriptional activity and VEGF expression in prostate cancer cells. This is due to deregulation of the PI3K pathway, which occurs as a result of PTEN loss of function in prostate cancer cells.
The downstream effector of PI3K-Akt termed the 'mammalian target of rapamycin (mTOR)' is recognized to regulate the translational process through increased phosphorylation of 4E-BP1 and p70S6K. The resultant activation of eIF4E and p70S6K leads to increased translation of HIF-1a mRNA. 9, 10 Recently, P276-00 was identified in our laboratory as a potent cyclin-dependent kinase inhibitor. 11 In vitro and in vivo xenograft studies have demonstrated that P276-00 is effective against a broad spectrum of human cancer cell lines. 12 We found that P276-00 inhibits HIF-1-dependent induction of luciferase in U251-HRE cells by inhibiting hypoxic accumulation of HIF-1a. In this study, prostate cancer cells (PC-3 and DU145) were used to explore the mechanism through which P276-00 inhibits activity of HIF-1. Unexpectedly, P276-00 did not downregulate hypoxia-mediated nuclear HIF-1a accumulation in these cells significantly, but reduced its transcriptional activity as evidenced by decreased mRNA levels of its target genes. It arrested the hypoxic PC-3 and DU145 cells in the G2/M phase, had antimigratory effect on them and inhibited angiogenesis potential of human endothelial cells in vitro. These results from P276-00 further stress the possibility that HIF-1a functions in an unresolved nature or condition.
Materials and methods

Cell culture
Human prostate cancer cell lines PC-3 and DU145 were obtained from ATCC (Rockville, MD, USA) and cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA). The media contained 2 mmol l À1 L-glutamine (Gibco, Grand Island, NY, USA), 100 U ml À1 penicillin and 100 mg ml À1 streptomycin (Gibco). Human umbilical vein endothelial cells (HUVECs) were obtained from Cascade Biologics (Invitrogen, Carlsbad, CA, USA) and cultured in the M-200 medium (Cascade Biologics) supplemented with low-serumgrowth supplements (Cascade Biologics), penicillin-G (100 U ml À1 ), streptomycin (100 mg ml
À1
) and amphotericin B (50 ng ml À1 ) (Gibco). All cell lines were maintained in a humidified incubator at 37 1C and 5% CO 2 . P276-00 was synthesized at Piramal Life Sciences (Mumbai, Maharashtra, India), dissolved in dimethyl sulfoxide at a concentration of 10 mmol l À1 (10 mM), stored at À20 1C until use, diluted in culture medium RPMI-1640 immediately before use and was used within 4 h. All reagents were purchased from Sigma Chemical (St Louis, MO, USA) unless otherwise mentioned.
Luciferase reporter assay
U251-HRE and U251-pGL3 cell lines were procured from Dr Giovanni (Hypoxia Laboratory, NCI, Frederick, MD, USA) and maintained as described by Rapisarda et al. 13 previously. U251-HRE cells stably express a recombinant vector in which the luciferase reporter gene is under control of three copies of a canonical HRE. In the U251-pGL3 control cell line, the luciferase reporter gene is under the control of a constitutively active promoter. These cells expressed high basal levels of luciferase under normoxic conditions and slightly lower levels under hypoxic conditions. U251-HRE cells were inoculated into 96-well white flatbottomed plates at 15 000 cells per well in a volume of 180 ml and incubated for 24 h at 37 1C, 5% CO 2 and ambient O 2 . Hypoxic conditions were created either by incubation in a modular hypoxia chamber (Billups Rothenberg, Del Mar, CA, USA, MIC 101) at 37 1C, 5% CO 2 and 1% O 2 or by adding a chemical inducer desferoxamine (DFX) (a hypoxia mimic) to the medium. DFX was observed to give better hypoxic stimulation without any significant cytotoxicity. DFX stimulation was used for all further experiments. For IC 50 determination, test compounds diluted at appropriate concentrations were added in a volume of 20 ml in the 96-well plates inoculated with U251-HRE cells. After 20 h incubation, the plates were removed and incubated at room temperature, 5% CO 2 and ambient O 2 for 1.5 h. In all, 40 ml of Bright Glo luciferase assay reagent (Promega, Madison, WI, USA) was added, and after 3 min, luminescence was measured using a POLARstar OPTIMA obtained from BMG Technologies (BMG Labtech GmbH, Ortenberg, Germany). Appropriate control cells (U251-pGL3) were treated identically, except that they were incubated at 37 1C, 5% CO 2 and ambient O 2 .
Western blot analysis
Confluent PC-3 and DU145 cells were seeded in tissue culture grade petri plates at a density of 1-2 Â 10 6 cells per plate. Cells were incubated in a humidified incubator for 18-24 h. Compounds were added according to concentrations, and appropriate controls and standards were taken. DFX at a final concentration of 60 mmol l À1 was added to each of the plates, except to the control (no DFX) plate. Plates were then incubated in a humidified incubator (5% CO 2 ) for different time intervals, that is, 8 or 24 h. Cells were trypisinized and harvested after incubation by centrifuging them at 1000 r.p.m. for 10 min. Cells were then washed twice with cold phosphatebuffered saline (PBS) and pelleted again. The pellet was then resuspended in 50-100 ml (according to the pellet) of CelLytic reagent with the protease inhibitor cocktail on ice. After lysis on ice, the lysate was centrifuged at 14 000 g for 20 min at 4 1C and the supernatant collected. Protein estimation was performed using the Bradford method. In all, 50 mg protein were separated on a (7.5-10%) tris-glycine gel, transferred to a polyvinylidene diflouride membrane (Millipore, Bedford, MA, USA) and probed with an anti-HIF-1a monoclonal antibody (BD Biosciences, San Jose, CA, USA), anti-p-Akt473 and anti-p-4E-BP1 antibodies (Cell Signaling Technology, Danvers, MA, USA), anti-cyclin D1 and anti-phospho-RbSer780 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-b-actin antibody (Sigma Chemical). Immunodetection was performed using the corresponding secondary horseradish peroxidase antibodies (Santa Cruz Biotechnology). Horseradish peroxidase activity was measured using enhanced chemiluminescence (Pierce, Rockford, IL, USA). Densitometric analysis of western blots was carried out using ImageJ 1.42 q software (NIH ImageJ, Biocompare, South San Franscisco, CA, USA).
Immunofluorescence Cells (0.1-0.3) Â 10 6 were seeded onto poly-L-lysinecoated glass coverslips and incubated overnight. Cells P276-00 inhibits HIF-1a SM Manohar et al were untreated or exposed to 60 mmol l À1 DFX for 8 h, in the absence or presence of different concentrations of P276-00 and processed for immunofluorescence. For HIF-1a immunofluorescence, cells were fixed in 3% paraformaldehyde in PBS for 20 min, then washed 5 min in PBS, permeabilized for 10 min in 0.2% Triton X-100 (Sigma Chemical) in PBS, followed by a final wash of PBS for 5 min; all steps were performed at room temperature. Non-specific binding was blocked by incubation in blocking buffer containing 10% FBS in PBS for 30 min at room temperature. Cells were incubated with primary mouse monoclonal anti-HIF-1a antibody (BD Transduction Labs, San Jose, CA, USA) diluted 1 : 100 in blocking buffer. Cells were washed three times with PBS/0.05% Triton X-100 for 5 min each, before incubation with secondary donkey anti-mouse fluorescein isothiocyanate-conjugated antibody (Chemicon International, Temecula, CA, USA) diluted 1:200 in blocking buffer for 2 h at room temperature in dark. After washing three times in PBS, coverslips were mounted onto slides using Ultra Cruz mounting medium (Santa Cruz Biotechnology). Images were captured using fluorescent microscope.
Reverse transcription-PCR
For reverse transcription-PCR analysis, total cellular RNA was isolated using TRI reagent (Sigma Chemical). Total RNA (3 mg) was used to synthesize first-strand cDNA with random primer and Moloney murine leukemia virus reverse transcriptase in a total reaction volume of 20 ml. PCR was performed on cDNA with 2 Â PCR master mix (Fermentas, Glen Burnie, MA, USA) and the corresponding primers. The following primers were used: VEGF, forward primer AACTTTCTGCTGTCTTGG and reverse primer TTTGGTCTGCATTCACAT; GLUT-1, forward primer TCCACGAGCATCTTCGAGA and reverse primer ATACTGGAAGCACATGCCC; HIF-1a, forward primer TATGACCTGCTTGGTGCTGA and reverse primer GGGAGAAAATCAAGTCGTGC, with annealing temperature of 60 1C and cycle no. 32; tubulin, forward primer TCTGTTCGCTCAGGTCCTTTTGGCC and reverse primer CGTACCACATCCAGGACAGA with annealing temperature of 55 1C and cycle no. 30. VEGF and GLUT-1 annealing temperature was 55 1C, cycle no. 32.
An aliquot of each reaction mixture was analyzed by electrophoresis on 1.5% agarose gel. After being stained with ethidium bromide, gel images were obtained using Quantity one software (Bio-Rad, Hercules, CA, USA).
Cytotoxicity assay
Cells were seeded at a density of 3000 cells per well (in 180 ml volume) in transparent 96-well tissue culture plates and allowed to incubate at 37 1C in 5% CO 2 incubator for 12-18 h. Test compounds were diluted in a medium at various concentrations, and 20 ml of 10 Â stocks were added to each well in triplicate. Plates were incubated for 48 h at 37 1C in 5% CO 2 incubator (normoxia) or 60 mmol l À1 DFX was added to them (hypoxia). After 48 h incubation, 20 ml of CellTiter 96 AQueous MTS Reagent (Promega) was added in each well, and plates were further incubated under the same incubation conditions for 4 h, followed by spectrophotometric absorbance at 490 nm on a Spectramax microplate reader (Molecular Devices, Downingtown, PA, USA). Data were analyzed to determine the IC 50 (concentration of compound that inhibited cell growth by 50%) for P276-00.
Analysis of cell-cycle distribution
PC-3 and DU145 cell lines were seeded in T-25 tissue culture flasks at a density of 1.0 Â 10 6 per flask. The next day, cells were untreated or exposed to 60 mmol l À1 DFX for 24 h, in the absence or presence of different concentrations of P276-00. Cells were harvested, washed in PBS, fixed in ice-cold 70% ethanol and stored at À20 1C. For fluorescence-activated cell sorting analysis, cells were washed twice with PBS to remove fixative and resuspended in PBS containing 50 mg ml À1 propidium iodide and 50 mg ml À1 RNaseA. After incubation at room temperature in dark for 30 min, cells were analyzed using flow cytometry.
PBMCs cytotoxicity assay
Blood was collected from healthy donors into Potassium EDTA vacutainer tubes (BD vacutainer). Peripheral blood mononuclear cells (PBMCs) were isolated using gradient centrifugation in Histopaque-1077 solution. Isolated PBMCs were suspended in RPMI-1640 culture medium containing 10% FBS, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. Cell concentration was adjusted to 1 Â 10 6 cells per ml. Viability as determined by trypan blue dye exclusion was uniformly X98%. Cell suspension (100 ml) was added to the wells of a 96-well culture plate. Concavalin A was added to the stimulated plate. The complete medium was added to the unstimulated plate and both plates were kept in the incubator for 16-18 h. After incubation and stimulation, compounds were added to both the plates in the same template and plates were kept for further incubation for 24-48 h. After incubation, the CellTiter 96 AQueous MTS Reagent was overlaid in each of the wells and the reading was taken on Spectramax microplate reader (Molecular Devices) at 490 nM and IC 50 evaluated.
siRNA-mediated RNA interference PC-3 cells were plated in 6-well plates with 2 Â 10 6 per well in complete medium. Cells were transfected with small-interfering RNA (siRNA) (HIF-1a-specific siRNA or non-specific siRNA, Qiagen, Valencia, CA, USA) using Lipofectamine 2000 Transfection Reagent (Invitrogen) as described by the vendor. For HIF-1a knockdown, cells were treated with 50 nmol l À1 siRNA. For this purpose, Lipofectamine 2000 reagent was diluted with serum-free medium and added to the diluted siRNA and incubated at room temperature for 20 min. The siRNA-Lipofectamine 2000 complex was added dropwise to cells in serum-free medium and incubated at 37 1C for 4 h, at which time, the medium with 10% FBS was added. To apply the drug P276-00 after siRNA transfection, 100 ml medium was removed and thoroughly mixed with a stock solution of P276-00 so as to yield a final concentration of 1 mmol l À1 . Cells were incubated further for another 20 h (for a total incubation of 24 h). At this time, cells were ready for collection for further experiments.
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Migration assay
PC-3 and DU145 cells in their respective media were grown to desired confluence in T-75 flasks. Upon reaching 60-80% confluency, cells were trypsinized and seeded at a density of (0.5-2.0) Â 10 6 per well in a sterile 6-well plate. The plates were incubated overnight in humidified CO 2 incubator (5% CO 2 ) at 371C under ambient oxygen levels. Cells were observed to form a confluent uniform monolayer on the complete surface of the well. The required number of cells for a confluent monolayer depends on both the particular cell type and size of dishes.
The cell monolayer was scraped in a straight line evenly to create a 'scratch' with a pipette tip. The first image of the scratches was acquired before compound addition.
After all first images were captured, the compounds to be tested along with standard compounds were added at various concentrations. The plates were then kept in the incubator for further incubation (24 h).
After incubation, the dish was placed under a phasecontrast microscope, reference point was matched, the photographed regions of the first image were aligned and the second image was acquired. For each image, distances between one side of the scratch and the other were measured.
Three-dimensional gel endothelial tube-formation assay
The BD Matrigel Matrix (BD Biosciences) was thawed at 4 1C overnight on ice (Matrigel may gel at slightly elevated temperatures in a refrigerator). Plates, tubes and tips were also pre-cooled on ice before use. Confluent HUVEC endothelial cells were cultured with the above-mentioned endothelial medium to desired confluence. For HUVECs, 60-80% confluence is recommended. Endothelial cell suspensions were prepared by trypsinizing the cell monolayers and resuspending the cells in the culture medium with 5-10% serum or with desired angiogenesis promoters. In all, 0.5-1 Â 10 6 cells per 180 ml were added (per well of a 24-well plate) of BD Matrigel Matrix, which had been thawed at 4 1C. Cells were allowed to adhere for 2-3 h. Subsequently, the compound was added at appropriate concentration. After 24 h of incubation, cells were observed under the microscope for tube formation and angiogenesis.
In vivo studies
Human prostate cancer (PC-3) cells were grown in RPMI-1640 containing 10% FBS and harvested. Cells were resuspended in saline at 10 million cells per 0.2 ml volume and placed on ice. Severe combined immunodeficient mice were injected in 0.2 ml volume subcutaneously on the right flank and observed daily for tumor appearance. When tumors attained a diameter of 5 mm, they were randomized into two groups (n ¼ 6). For control (group I), water was administered every day intraperitoneally for 10 days, and 50 mg kg À1 P276-00 (group II), P276-00 solution in water was also administered every day intraperitoneally for 12 days.
Statistical analysis
Statistical comparison was made using GraphPad Prism (versions 3.0. and 210 5.0, GraphPad Software, La Jolla, CA, USA) software in which one-way analysis of variance and Tukey's multiple comparison post tests were used to determine significant differences between several treatment groups. Student's paired t-test was used when only two groups were compared. Data are presented as mean ± s.e.m. of at least three independent experiments with triplicate. Statistical significance was evaluated by calculating P-values. Differences where Po0.05 were considered statistically significant (*Po0.05; **Po0.01; ***Po0.001).
Results
Identification of P276-00 as a HIF-1 pathway inhibitor from a cell-based screening assay
To identify novel small molecules targeting the HIF-1 pathway, a human glioma cell line U251-HRE, which stably expresses a hypoxia-responsive luciferase reporter gene was used. It was observed that there was a significantly higher reporter gene expression (P ¼ 0.0121) upon stimulating cells with DFX-a hypoxia mimic than incubating them under 5% CO 2 , 1% O 2 conditions in a hypoxic chamber (Figure 1a ) without any significant cytotoxicity (data not shown). Hence, DFX stimulation was used for all further experiments for creating a hypoxic environment. U251-HRE cells were used for screening of inhibitors acting on any steps involved in the transactivation of HREs. Such inhibitors could act, for example, by decreasing HIF-1a expression or activity, decreasing nuclear localization of HIF-1a or decreasing binding between HIF-1a and coactivators and/or HRE sequence. After 24 h of treatment under hypoxia, P276-00 displayed an IC 50 of 0.095 ± 0.007 mmol l À1 against hypoxia-induced luciferase enzymatic reporter activity (Figure 1b) . A parallel experiment was performed to exclude any possibility of inhibition of luciferase expression in a nonspecific and/or HIF-1-independent manner. This was performed on U251-pGL3 cells in which the luciferase 
P276-00 inhibits HIF-1a
SM Manohar et al reporter gene is under control of a constitutively active promoter. These cells express high basal levels of luciferase under normoxic conditions and slightly lower levels under hypoxic conditions (data not shown). The specificity index was calculated, obtained by dividing IC 50 in U251-pGL3 by IC 50 in U251-HRE, which provides an indication of relative specificity toward inhibition of HIF-1-dependent transcription. P276-00 had a specificity index X10 (chosen as arbitrary threshold), indicating that it had minimal or no activity on the constitutive expression of luciferase in the U251-pGL3 control cell line.
Inhibition of HIF-1a accumulation by P276-00 in U251-HRE cells is independent of proteasomal degradation
Hypoxia-inducible factor-1a is degraded mainly through the proteasome pathway. Blockade of proteasome function by proteasome inhibitors increases the accumulation of HIF-1a protein under normoxic conditions. To check whether P276-00 inhibited HIF-1a accumulation by promoting degradation of the protein, U251-HRE cells were treated for 8 h with proteasome inhibitor 20 mmol l À1 MG132 and 3 Â IC 50 (3X) P276-00 and/or with 60 mmol l À1 DFX and 3X P276-00. As expected, treatment with DFX or MG132 resulted in accumulation of HIF-1a (Figure 2 ). P276-00 inhibited the accumulation of HIF-1a protein despite proteasome inhibition, indicating that P276-00 decreases HIF-1a protein accumulation through a pathway independent of proteasome degradation in this particular cell line.
Effect of P276-00 on hypoxia-mediated accumulation of HIF-1a in the nucleus
The ability of P276-00 to inhibit HIF-1a activity was tested by evaluating levels of HIF-1a protein expressed in the nuclei of PC-3 and DU145 cells exposed to hypoxia. Cells were seeded onto coverslips, and the next day were untreated or exposed to DFX which is a hypoxia mimic, in the absence or presence of different concentrations of P276-00 and processed for immunofluorescent microscopy ( Figure 3) . Treatment of cells with DFX induced accumulation of HIF-1a protein within the nucleus (green signal). P276-00 caused slight changes in the accumulation of cellular HIF-1a protein after 8 h exposure under hypoxia in both the cell lines. DAPI staining was used to reveal the DNA within the nuclei (blue signal).
P276-00 inhibits activation of the PI3K/Akt/mTOR pathway during hypoxia
The PI3K/Akt pathway is activated by hypoxia in certain cell types, 14, 15 and interference with Akt reduces accumulation of HIF in response to hypoxia. 16 Treatment with P276-00 in the presence of DFX resulted in decreased phosphorylation of Akt and 4E-BP1 (Figures 4a and b) . Thus, in hypoxic prostate cancer cells, P276-00 treatment ; proteasome inhibitor) in the presence and absence of P276-00 (3 Â IC 50 ) for 8 h, and then protein extracts were prepared as described in 'Materials and methods' section. HIF-1a inhibition by P276-00 was independent of proteasome activity. DFX, desferoxamine; HIF-1a, hypoxia-inducible factor-1a.
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P276-00 downregulates cyclin D1 levels and phosphoRbSer780 levels under hypoxic conditions
Effect of P276-00 on its key targets cyclin D1 and phospho-RbSer780 was tested in the presence of DFX by western blot analysis. It was observed that P276-00 inhibited both these protein levels in a dose-and timedependent manner in the PC-3 cell line (Figure 4a ). DU145 cells did not exhibit downregulation of cyclin D1 levels in response to P276-00 treatment (Figure 4b ).
Effect of P276-00 on HIF-1a target gene expression
To study whether inhibition of HIF-1a would result in decreased expression of its target genes, the expression of known HIF-1a target genes VEGF and GLUT-1 was analyzed. In both PC-3 and DU145 cells cultured in the presence of DFX, inhibition of VEGF mRNA upregulation was observed after P276-00 treatment in a dose-dependent manner (Figure 4c) . In both the cell lines, VEGF but not GLUT-1 mRNA levels were induced by DFX treatment and inhibited in a concentrationdependent manner after P276-00 treatment. These results indicate that P276-00 is effective in inhibiting the activation of the HIF-1 target gene VEGF, which is vital to many aspects of tumor biology such as angiogenesis.
P276-00 shows synergism with HIF-1a siRNA in PC-3 cells
A moderate reduction of HIF-1a protein levels of 450 and 52% was observed after treatment with P276-00-or HIF-1a-specific siRNA, respectively. Transfection with , that is, 5X) for 8 and 24 h, and then protein extracts were prepared as described in the 'Materials and methods' section. (c) P276-00 specifically inhibits VEGF and GLUT-1 mRNA expression under hypoxia in a dose-dependent manner. However, HIF-1a mRNA levels remained unchanged. DFX, desferoxamine; HIF-1a, hypoxia-inducible factor-1a; VEGF, vascular endothelial growth factor.
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Effect of P276-00 on cell proliferation under hypoxia P276-00 has been demonstrated to possess potent antitumor activity in vitro and in vivo. 11 To compare the cytotoxic activity of P276-00 under normoxia and hypoxia in vitro, PC-3 and DU145 cells were treated with different concentrations of P276-00 under normoxia in the presence of DFX for 48 h. As expected, under normoxia, P276-00 exhibited significant concentrationdependent cytotoxic activity in both the cell lines, but in the presence of DFX, enhanced cytotoxicity was seen in PC-3 cells but not in DU145 (Figure 6a PC-3: P ¼ 0.0453, DU145: P ¼ 0.2596). The data indicate that P276-00 probably exerts a cytostatic effect under hypoxia rather than a cytotoxic effect. In addition, to exclude the possibility of toxicity caused on normal cells, we examined the effect of P276-00 on non-malignant cells. PBMCs isolated from healthy human donors were stimulated by addition of concavalin A and exposed to P276-00 for 48 h, followed by cytotoxicity estimation using MTS assay. In PBMCs isolated from both the donors, some level of cytotoxicity was observed in unstimulated cells; however, in concavalin A-stimulated cells, P276-00 was observed to be significantly more cytotoxic (donor 1: P ¼ 0.009, donor 2: P ¼ 0.0048) (Figure 6b ).
Effect of P276-00 on cell-cycle progression under hypoxia
To better understand the mechanism of inhibition of cell proliferation by P276-00 under hypoxia, the distribution P3155 or 50 nM HIF-1a siRNA under hypoxia (that is, in the presence of DFX), and HIF-1a protein expression analysis was carried out using western blotting. Cotreatment with HIF-1a siRNA and P276-00 resulted in complete abrogation of HIF-1a protein after 24 h treatment under hypoxia. DFX, desferoxamine; HIF-1a, hypoxia-inducible factor-1a; siRNA, small-interfering RNA.
P276-00 inhibits HIF-1a SM Manohar et al of PC-3 and DU145 cells in the different phases of the cell cycle was analyzed after treatment with P276-00 (3 or 5 or 7 mmol l À1 concentration) for 24 h in the presence of DFX. At the end of treatment, there were marked and consistent changes in the cell cycle. The number of cells in the G2/M phase increased in both the cell lines with a concomitant decrease in treated cells in the G0/G1 and S phases. The difference between the mean percentage of control and treated cells in the G2/M phase was statistically significant in both cell lines (PC-3: Po0.0001, DU145: P ¼ 0.0004). Concentration-dependent effects of P276-00 on the proportion of cells in the G2/M phase of the cell cycle are shown in Figure 7 .
Effect of P276-00 on cell migration
The effect of P276-00 on the migratory activity of PC-3 (highly metastatic) and DU145 (moderately metastatic) prostate cancer cells was assessed by a wound-healing assay (Figure 8a) . The quantified results showed in Figure 8b indicate that over 24 h treatment, P276-00 inhibited the motility of these cells and hence wound healing in vitro in a dose-dependent manner (PC-3: P ¼ 0.0586, DU145: P ¼ 0.118).
Effect of P276-00 on tube formation of HUVECs
We next evaluated the effect of P276-00 on the formation of functional tubes by HUVECs plated on the Matrigel, a reconstituted extracellular matrix preparation. Serum was used as the stimulator in this study. 17 In the control group stimulated with serum, HUVECs rapidly aligned with one another and formed tube-like structures resembling a capillary plexus within 24 h, which required cell-matrix interaction, intercellular interaction and cell motility. P276-00 prevented FBS-stimulated tube formation of HUVECs, and no cytotoxicity was observed at this concentration (Figure 8c) . Therefore, P276-00 was revealed to interfere with the ability of HUVECs to form the in vitro vessel-like tube.
Antitumor effect of P276-00 in a xenograft model of prostate cancer
To confirm the in vivo activity of P276-00, the antitumor efficacy of P276-00 in a xenograft model of PC-3 was studied. P276-00 administered intraperitoneally at 50 mg kg À1 daily for 12 days showed significant reduction in PC-3 tumor growth compared with that observed in the vehicle-treated group (Figure 9a ). Mice treated with P276-00 had no significant weight loss while on the study drug (data not shown). The average tumor weight on day 12 for control and P276-00 was 365.3 ± 95.66 and 201.5 ± 61.08 mg, respectively. The calculated percentage of growth inhibition on day 12 after randomization was 54.46% and was statistically significant (P ¼ 0.0468).
Discussion
HIF-1a is the downstream mediator of hypoxic and nonhypoxic signaling pathways, which have a crucial role in cancer progression. HIF-1a is overexpressed in human cancers due to hypoxia-dependent and/or hypoxiaindependent pathways, and overexpression of HIF-1a has been implicated as a poor prognostic indicator in various tumors. Therefore, HIF-1 is an attractive target for cancer therapy. 18 Several approaches have been used to inhibit HIF-1a expression and/or activity, which include antisense or siRNA strategies, 19, 20 inhibition of proteins that modulate HIF-1 activity, [21] [22] [23] [24] signal transduction pathways involved in HIF-1a activation [25] [26] [27] microtubules, topoisomerase I 28 or mechanisms not clearly defined. 29 A number of anticancer drugs have been shown to inhibit HIF, but none of these drugs have been shown to directly and specifically target HIF-1. [30] [31] [32] [33] [34] [35] [36] [37] Moreover, only a few of the reported HIF-1a inhibitors demonstrated antitumor activity in vivo. 38, 39 This lack of specificity increases the difficulty in attributing any antitumorigenic effects of these drugs specifically to the inhibition of HIF-1a. However, this does not disqualify these drugs as potential anticancer agents; indeed, the fact that these drugs target multiple pathways may be beneficial if the other targets are also involved in tumorigenesis.
In this study, we identified P276-00 to be a small molecule inhibitor of the HIF-1 pathway. We have evaluated P276-00 earlier for antitumor activity in vitro and in vivo. It belongs to the flavone class of compounds and is a potent Cdk inhibitor. To determine whether P276-00 is an inhibitor of HIF-1 transcriptional activation, engineered cell lines that express the luciferase reporter gene in a HIF-1-inducible manner were used. U251-HRE cells express high levels of luciferase consistently under hypoxia, whereas U251-pGL3 constitutively expressed luciferase under normoxia. In U251-HRE cells, P276-00 inhibited hypoxic induction of luciferase expression by a factor of X50% at the concentration of 1 mmol l À1 . Additional experiments were aimed at confirming the results of the primary screen and identifying IC 50 (the dose at which there was 50% inhibition). Parallel experiments were conducted to exclude any possibility of inhibition of luciferase expression in a non-specific and/or HIF-1-independent manner. The IC 50 of P276-00 was determined in U251-pGL3 under normoxia, and the specificity index was calculated, obtained by dividing the IC 50 in U251-pGL3 by the IC 50 in U251-HRE. The specificity index value provides an indication of relative specificity toward inhibition of HIF-1-dependent transcription. As hypoxia induces an increase in HIF-1a protein stability and transcriptional activity, we hypothesized that the inhibition of HIF-1 transcriptional activity could be due to a decrease in the levels of HIF-1a. This was confirmed by western blot analysis in which the hypoxia mimic DFX or the proteasome inhibitor MG132 was used to induce HIF-1a protein levels. Under both these conditions, P276-00 downregulated HIF-1a protein levels significantly, thus implying that it mediated its effect independent of proteasomal activity.
Previous studies have shown that upregulation of HIF1a is an early event in prostate carcinogenesis, and that HIF-1a may be a future biomarker for premalignant lesions of the prostate. 40 Du et al. 41 have confirmed the high levels of HIF-1a in prostate cancer as compared with BPH and normal tissue. Hence, prostate cancer cell lines were selected for elucidation of mechanism of action of P276-00 under hypoxia. Mutation of PTEN in PC-3 cells leads to high levels of HIF-1a and VEGF expression. 42 Here, we demonstrate that in PC-3 and To compare the effect of HIF-1a siRNA and P276-00 on HIF-1a protein expression, western blot analysis was performed. PC-3 cells were transfected with suboptimal concentrations of siRNA or P276-00 or both, ie, 50 nM HIF-1a-specific siRNA or P276-00 (1 mM) or both under hypoxia. The results showed that hypoxia-induced HIF1a protein expression was partially suppressed on transfection with HIF-1a siRNA alone or P276-00 treatment alone. Transfection with HIF-1a siRNA combined with P276-00, both used at suboptimal concentrations, resulted in complete abrogation of active HIF-1a expression. Thus, both these agents when used together showed a synergistic effect.
In eukaryotes, most translation is cap dependent with regulation of eIF4E availability serving as a major control point. Under normoxia, upregulation of translation through the PI3K/Akt/mTOR pathway acts to promote HIF-1a protein accumulation and expression of eIF4E is also sufficient to elevate HIF-1a protein levels. 43 Although further studies are required to determine the relative contribution of the PI3K/Akt pathway to P276-00 mediated HIF-1a inhibition, our results clearly show that P276-00 also acts through inhibition of phosphorylation of Akt and 4E-BP1 in hypoxia. As expected, it was also observed to inhibit its key target protein cyclin D1 levels and Rb phosphorylation. Thus, in addition to HIF-1a inhibition, anticancer activity of P276-00 under hypoxia can be attributed to this pathway as well.
Our previous data show that P276-00 has significant cytotoxic effect on a wide spectrum of cancer cell lines, including lung, prostate, breast, colon, ovarian and melanoma. 12 However, in spite of being a HIF-1 inhibitor, P276-00 inhibits HIF-1a SM Manohar et al it did not show enhanced cytotoxic activity on prostate cancer cells under hypoxia. Hence, to further study its effects on cell cycle under hypoxia, flow cytometric analysis of PC-3 and DU145 cells cultured for 24 h under hypoxia in a medium containing various concentrations of P276-00 was carried out. A dose-responsive accumulation of cells in the G2/M phase of the cell cycle was observed, thus supporting the hypothesis that it exerted a cytostatic effect on hypoxic cancer cells. Recently, a novel tirapazamine (so far the most advanced hypoxia selective drug) derivative N-ethoxymethyl-3-amino-1,2,4-benzotriazine-1,4-dioxide was found to induce G2/M arrest in human non-small cell lung cancer cells under hypoxia. 44 We next investigated whether P276-00 would also discriminate between non-transformed proliferating cells and resting cells. Freshly isolated PBMCs were incubated with the lectin concavalin A, which is known to cause proliferation of PBMCs.
45 P276-00 induced significantly higher cytotoxicity in proliferating PBMCs than in non-proliferating PBMCs. This suggests that the basis for P276-00-induced apoptosis in transformed cells is due to their mitogenic nature, thus confirming our previous results that the compound has selectivity for fast-growing cancer cells versus slowgrowing normal cells.
The hallmark of tumor cells is their ability to migrate and metastasize. Prostate cancers are known to metastasize in a high percentage of the cases, which is obviously linked to a poor prognosis. Therefore, the potential effect of P276-00 on prostate cancer cell migration was tested using the wound-healing assay, which is a classic and commonly used method. The results demonstrated that P276-00 inhibited cell migration of PC-3 and DU145 cells in a dose-dependent manner in the presence of serum without showing any toxicity. One of the most widely used in vitro assays to model the reorganization stage of angiogenesis is the tube-formation assay. The assay measures the ability of endothelial cells, plated at subconfluent densities with the appropriate extracellular matrix support, to form capillary-like structures. P276-00 effectively blocked tube formation by HUVEC cells as shown in Figure 7 . Taken together, these results suggest that P276-00 inhibits cell migration and angiogenesis probably through HIF-1a inhibition. Owing to promising in vitro results of our identified HIF-1a inhibitor, we examined tumor growth inhibition due to P276-00 treatment. The human xenograft model showed efficacy of P276-00 in prostate cancer when given by an intraperitoneal route. It showed significant antitumor activity with 54% growth inhibition.
Over the past decade, the number of novel, singletarget drugs have fallen much behind expectations. As the development of cancer is a dynamic and multistage process, in which a large number of genes and proteins are involved, to combat the disease, the drug-discovery paradigm is shifting from 'one-drug, one-target' to 'onedrug, multiple-targets. ' In addition, the heterogeneity of tumor cells within selected neoplastic lesions, as well as the redundancy of proliferative and survival pathways present in cancer cells favor the development of single drugs that affect multiple pathways. Here, we show that P276-00, besides being a cyclin-dependent kinase inhibitor, has additional roles under hypoxic conditions, that is, inhibition of the PI3K/Akt pathway, downregulation of hypoxia-mediated HIF-1 transcriptional activity and reduction of the VEGF paracrine secretion from tumor cells. Its antiangiogenic and antimigratory activity was also revealed by its direct action on endothelial cells and prostate cancer cells in vitro. Thus, P276-00 could be limiting the process of neo-vascularization, correlating with its demonstrated antitumor activity in vivo. Given its low toxicity profile, its demonstrated antitumor activity in the prostate cancer xenograft model and its potential to inhibit the multiple pathways under hypoxia, P276-00 should be considered as an effective therapy for prostate cancer. P276-00 inhibits HIF-1a SM Manohar et al
